首页> 美国卫生研究院文献>Clinical and Developmental Immunology >Tolerance Induction Strategies in Vascularized Composite Allotransplantation: Mixed Chimerism and Novel Developments
【2h】

Tolerance Induction Strategies in Vascularized Composite Allotransplantation: Mixed Chimerism and Novel Developments

机译:血管化复合同种异体移植的耐受诱导策略:混合嵌合体和新进展。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Since the start of the clinical vascularized composite allotransplantation (VCA) era over a decade ago this field has witnessed significant developments in both basic and translational research. Transplant tolerance, defined as rejection-free acceptance of transplanted organs or tissues without long-term immunosuppression, holds the potential to revolutionize the field of VCA by removing the need for life-long immunosuppression. While tolerance of organ and vascularized composite transplants may be induced in small animal models by a variety of protocols, only mixed-chimerism-based protocols have successfully bridged the gap to preclinical study and to clinical trial in solid organ transplantation to date. In this paper we review the mixed-chimerism approach to tolerance induction, with specific reference to the field of VCA transplantation, and provide an overview of some novel cellular therapies as potential adjuvants to mixed chimerism in the development of tolerance induction protocols for clinical vascularized composite allotransplantation.
机译:自从十年前临床血管化复合同种异体移植(VCA)时代开始以来,该领域在基础研究和转化研究中均取得了重大进展。移植耐受性定义为无需长期免疫抑制就可以无排斥地接受移植的器官或组织,通过消除对终生免疫抑制的需求,有可能彻底改变VCA领域。虽然在小动物模型中可以通过多种方案诱导器官和血管复合移植的耐受性,但迄今为止,只有基于混合嵌合体的方案才成功地弥合了临床前研究和实体器官移植的临床试验之间的差距。在本文中,我们综述了混合嵌合体诱导耐受的方法,特别是针对VCA移植领域,并概述了一些新的细胞疗法作为混合嵌合体潜在佐剂在临床血管化复合物耐受诱导方案开发中的应用。同种异体移植。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号